International Stem Cell Corporation to Present at 65th American Academy of Neurology Annual Meeting

CARLSBAD, CA--(Marketwire - Mar 5, 2013) - International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today that it will present results of pre-clinical studies of Parkinson's disease (PD) at the 65th American Academy of Neurology Annual Meeting at the San Diego Convention Center, San Diego, California on Wednesday, March 20th, 2013.

At the meeting Dr. Ruslan Semechkin, Vice President of Research and Development for ISCO, will present results from efficacy studies of stem cell derived neuronal cells for the treatment of Parkinson's disease. Results and conclusions from both rodent and non-human primate models of the disease will be presented.

The American Academy of Neurology Annual Meeting is one of the world's most important annual events for neurologists and neuroscience professionals and the largest such international meeting of its kind with more than 12,000 attendees at last year's meeting.

About International Stem Cell Corporation

International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs) hence avoiding ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.

To receive ongoing corporate communications via email, visit: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0

To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell

More here:
International Stem Cell Corporation to Present at 65th American Academy of Neurology Annual Meeting

Part 16, after stem cell treatment, 3 months already! 2march2013 – Video

Part 16, after stem cell treatment, 3 months already! 2march2013
Please note I made an error saying the date, it was the 2 March 2013 My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it #39;s in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video.

By: Kina Diamond

Continue reading here:
Part 16, after stem cell treatment, 3 months already! 2march2013 - Video

Part 17, after stem cell treatment, exercises

Part 17, after stem cell treatment, exercises feeling better today, 3march2013
My name is Carole St-Laurent, I am from Rimouski, Quebec, Canada. I have a Spinal Muscular Atrophy from birth, it #39;s in the family of Muscular Dystrophy. I received a stem cell treatment on the 28th of November 2012 at the "Integra Medical Center" in Nuevo Progresso Mexico, by Dr. Omar Gonzalez. This is a follow-up video.

By: Kina Diamond

Read the original:
Part 17, after stem cell treatment, exercises

VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)

SOUTH SAN FRANCISCO, CA--(Marketwire - Mar 4, 2013) - VistaGen Therapeutics, Inc. ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, and Celsis In Vitro Technologies ("Celsis"), the premier global provider of specialized in vitro products for drug metabolism, drug-drug interaction and toxicity screening, have entered into a new strategic collaboration agreement. The comprehensive goal of the agreement is to characterize and functionally benchmark VistaGen's human liver cell platform, LiverSafe 3D, for studying and predicting human liver drug metabolism.

VistaGen will utilize Celsis' experience and expertise in in vitro drug metabolism to help validate VistaGen's human liver cell platform.In this strategic collaboration Celsis will not only validate VistaGen's stem cell-derived liver cells in traditional pharmaceutical metabolism assays, but will also determine genetic variations in VistaGen's pluripotent stem cell lines that are important to drug development.In addition, VistaGen will utilize Celsis' human cadaver-derived liver cells, currently used throughout the pharmaceutical industry for traditional drug metabolism assays, as reference controls with which to monitor and benchmark the functional properties of VistaGen's human liver cell platform.

With the assistance of Celsis scientists, VistaGen aims to achieve four key objectives:

"As an industry leader in the development of in vitro primary hepatocyte technology, Celsis has extensive resources to aid us in the benchmarking of our novel liver cell-based platform to industry standards," said H. Ralph Snodgrass, PhD, VistaGen's President and Chief Scientific Officer. "We anticipate this collaboration will lead to the further validation of our LiverSafe 3D system for predicting liver toxicity and drug metabolism issues long before costly human clinical trials."

"This is another example of our long-term dedication to using the power of human pluripotent stem cells as the basis of more predictive in vitro tools for drug discovery and development," concluded Dr. Snodgrass.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism screening. VistaGen's drug rescue activities combine its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube, with modern medicinal chemistry to generate novel, safer chemical variants (Drug Rescue Variants) of once-promising small molecule drug candidates. These are drug candidates discontinued by pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories, after substantial investment in discovery and development, due to heart or liver toxicity or metabolism issues. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

VistaGen's small molecule prodrug candidate, AV-101, has completed Phase 1 development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects millions of people worldwide.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen's Facebook page at http://www.facebook.com/VistaGen.

About Celsis In Vitro Technologies

Read the original here:
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D(TM)

YaFarm Technologies Announces ISCI Release of Patient Publications

PITTSTON, ME--(Marketwire - Mar 4, 2013) - YaFarm Technologies, Inc. ( PINKSHEETS : YFRM ) (YaFarm, or the Company) is pleased to announce the Integrative Stem Cell Institute (ISCI) has released three proprietary documents for patients seeking stem cell based therapies. These documents concerning stem cell procedures will be available to both new and existing patients.

The three articles that the ISCI has published are:

The ISCI Vetting Stem Cell Clinics provides a clear and concise overview of areas patients need to investigate prior to seeking stem cell therapy. The article provides information on how to evaluate claims made by the clinic, the importance of independent review of the treatments, as well as an explanation about the importance of long-term follow up. http://iscelli.com/vettingstemcellclinics.php

20 Questions to Ask a Physician provides critical questions patients should ask before seeking treatment. Patients are urged to read the article, which discusses how cells are removed and injected into the patients, as well as how to determine the qualification of the physicians. http://iscelli.com/questionstoask.php

Patient Rights details patient rights and includes a thorough discussion on how patients should be treated by clinics and physicians. It also sets expectations of treatment while defining the level of care and service to be afforded to all patients. The ISCI believes patients should understand their role in a clinical study and understand there can be no guarantees. http://iscelli.com/patientsrights.php

"The ISCI has set the bar extremely high," said David Audley, CEO of the ISCI. "No other clinic has taken such a bold, public stance on patient care and safety. These documents are a powerful collection of questions and observations that range from collection and processing of cells, to outcome tracking and access to access to medical records. These are the most complete and comprehensive set of views to protect and educate patients. We believe we have set the standard for every clinic, while enshrining transparency and protecting patient safety."

About Integrative Stem Cell Institute (ISCI)The Integrative Stem Cell Institute (ISCI) is a premier provider of point-of-care, stem cell-based therapies for patients from around the world. With a state of the art laboratory housed within the Hospital Galenia in Cancun, Mexico, the ISCI combines the most advanced scientific application of stem cells with second to none medical care within the structure of adaptive clinical trials to effectively track long term outcomes and assure patient safety. More information on the Integrative Stem Cell Institute is available at http://www.iscelli.com

SAFE HARBOR STATEMENT

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition, adequate financing, and other material risks. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance, or achievements to be materially different from the statements made herein.

Read more:
YaFarm Technologies Announces ISCI Release of Patient Publications

New Treatment for Sickle Cell Brings Hope and a Cure to Chicago Area Patients

Newswise Two brothers have been cured of their sickle cell disease at the University of Illinois Hospital & Health Sciences System using a relatively uncommon type of stem cell transplant that is performed without chemotherapy.

Their transplants were possible thanks to a third brother who was a match for both, against long odds.

Julius and Desmond Means never imagined life without sickle cell. The brothers, ages 25 and 19, have spent their lives in and out of hospitals, each suffering from different complications of the disease.

Growing up, they tired easily and couldn't keep up with their friends. As they grew older, the disease caused bone damage and affected Julius's lungs. Desmond's organs were also being damaged, and he was jaundiced.

For either young man to receive a transplant, a healthy sibling who is a compatible donor was needed. An acceptable match requires that at least eight of 10 known human leukocyte antigen (H.L.A.) genes be identical between donor and recipient.

Julius and Desmond's healthy older brother Clifford, 27, matched 10 of 10 H.L.A. genes with both of them -- an occurrence of "extremely low" likelihood, according to Dr. Damiano Rondelli, director of stem-cell transplantation at UI Health. The men's mother, Beverly Means, also noted the good fortune.

"I had won the lottery of health," she said.

In preparation for the transplant, Clifford was given medication to increase the number of stems cells released from the bone marrow into the bloodstream. His blood was then processed through a machine that collects white cells, including stem cells. The stem cells were frozen until the transplants.

Last May, Julius received his transplant at UI Hospital. He was given medication to suppress his immune system and one small dose of total body radiation right before the transplant. Then the frozen bags of stem cells were thawed and hung by IV pole for infusion into him.

Then in September, Desmond received his stem cell transplant.

See more here:
New Treatment for Sickle Cell Brings Hope and a Cure to Chicago Area Patients

Can we trust your doctor? – Video

Can we trust your doctor?
http://www.rejuvenare.com 1 888-988-5456 Many people who feel that stem cell therapy is the answer they have been searching for are concerned that, as of today, they need to travel for the simple procedure and they are unsure of the level of treatment they will receive. Recently the former head of a multi-national pharmaceutical company turned to Rejuvenare for help with the debilitating effects of Parkinson #39;s disease. In this short video clip - you will see the interview with his son and wife on their impression of the level of care their loved one received. This interview was done 2 days after the procedure. The improvement to their family member was apparent within hours - although they were all a little tired, they were also appreciative... Are you or someone you know a candidate for adult stem cell therapy? Visit http or call 888-988-5456 to find out.

By: Carlo Velarde

Read this article:
Can we trust your doctor? - Video

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy – Video

Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

Read more from the original source:
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy - Video

Myotonic Muscular Dystrophy Before and After Stem Cell Therapy – Video

Myotonic Muscular Dystrophy Before and After Stem Cell Therapy
Myotonic Muscular Dystrophy Improvement in a week after Stem Cell Therapy He is a known case of Myotonic MD with history of gradual onset of progressive lower extremities muscle weakness since age of 25 years. He also has history of delayed milestones. His weakness is progressive in nature. He falls while walking so walks with human support only. He has complaints of early fatigue and slurred speech due to tongue hypertrophy. He has atrophy of proximal muscles of all extremities. He has modified independence in almost all ADL. Neurologically, hypotonic, hyporeflexic. On examination: lower limb distal muscles are 0/5 on MMT while proximal muscles are having 2++/5 on MMT. Upper extremities left side proximal muscles are 1++/5 while right side proximal muscles are 3 #713;/5, distal muscles are 3++/5 in upper extremities. Functionally, modified independence in all ADL. On FIM he scores 99. After Stem Cell Treatment 1. His face looks more fresh. 2. His neck used to fall back previously but now he can control his neck well in each movement. 3. Back muscle strength has improved. 4. Bridging is better now. He can lift his back more up now which he couldn #39;t do at all. 5. His stamina has improved. 6. His shoulder strength has improved. Shoulder shrugging is better now. Active shoulder flexion, range of motion is more now. 7. Side lying to sitting he can do without any support which was not possible before. 8. Drooling of saliva from mouth in night is completely stopped. 9. His legs used ...

By: neurogenbsi

View original post here:
Myotonic Muscular Dystrophy Before and After Stem Cell Therapy - Video

Alternatives to knee replacement… fibroblast growth factor as an aid to stem cell cartilage repair – Video

Alternatives to knee replacement... fibroblast growth factor as an aid to stem cell cartilage repair
http://www.stemcellsarthritistreatment.com In our series on alternatives to knee replacement, let #39;s go over some of the growth factors needed for cartilage growth and maintenance... let #39;s talk about Fibroblast growth factor Fibroblast growth factors (FGF) are proteins that play a major role in the development of normal cartilage and bone. Genetic mutations that cause deficiencies of this protein result in significant skeletal abnormalities. In rat studies, FGF has demonstrated impressive abilities to stimulate cartilage repair in osteoarthritis. On the other hand FGF, under certain circumstances has been shown to inhibit the effects of other growth factors such as Insulin-like growth factor. Its use as an adjunctive ingredient in the application of mesenchymal stem cells for cartilage repair bears watching. http

By: Nathan Wei

Follow this link:
Alternatives to knee replacement... fibroblast growth factor as an aid to stem cell cartilage repair - Video